Delia Jane Nelson

List of Publications by Year
in descending order

44 papers	2,112 citations	257450 24 h-index	254184 43 g-index

44 all docs	44 docs citations	44 times ranked	2949 citing authors

#	Article	IF	Citations
1	Developing a translational murineâ€toâ€canine pathway for an <scp>IL</scp>â€2/agonist <scp>antiâ€CD40</scp> antibody cancer immunotherapy. Veterinary and Comparative Oncology, 2022, 20, 602-612.	1.8	4
2	Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma. Frontiers in Aging, 2022, 3, .	2.6	7
3	CD8+ cytotoxic T cell responses to dominant tumor-associated antigens are profoundly weakened by aging yet subdominant responses retain functionality and expand in response to chemotherapy. OncoImmunology, 2019, 8, e1564452.	4.6	6
4	Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. Frontiers in Immunology, 2019, 10, 3074.	4.8	6
5	Aged neutrophils accumulate in lymphoid tissues from healthy elderly mice and infiltrate Tâ€•and Bâ€cell zones. Immunology and Cell Biology, 2018, 96, 831-840.	2.3	30
6	Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia. Frontiers in Genetics, 2018, 9, 526.	2.3	42
7	The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy. Frontiers in Medicine, 2018, 5, 337.	2.6	2
8	Elderly dendritic cells respond to LPS/IFN-Î³ and CD40L stimulation despite incomplete maturation. PLoS ONE, 2018, 13, e0195313.	2.5	17
9	A review of the importance of immune responses in luminal B breast cancer. OncoImmunology, 2017, 6, e1282590.	4.6	5
10	Aging and cancer: The role of macrophages and neutrophils. Ageing Research Reviews, 2017, 36, 105-116.	10.9	171
11	Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules. Ageing Research Reviews, 2017, 38, 40-51.	10.9	27
12	Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. OncoImmunology, 2016, 5, e1082028.	4.6	20
13	Murine mesothelioma induces locally-proliferating IL-10⁺TNF-Î±⁺CD206^{â^'}CX3CR1⁺M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy. OncoImmunology, 2016, 5, e1173299.	4.6	49
14	Mesothelioma Tumor Cells Modulate Dendritic Cell Lipid Content, Phenotype and Function. PLoS ONE, 2015, 10, e0123563.	2.5	37
15	Sarcostemma viminale activates macrophages to a pro-inflammatory phenotype. Comparative Clinical Pathology, 2015, 24, 817-826.	0.7	3
16	Bloodâ€"brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immunity and Ageing, 2015, 12, 2.	4.2	221
17	The â€œTrojan Horseâ€•Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment. Journal of Immunology Research, 2014, 2014, 1-14.	2.2	37
18	Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?. Experimental Gerontology, 2014, 54, 53-57.	2.8	28

#	Article	IF	Citations
19	Lipid-laden partially-activated plasmacytoid and CD4â^'CD8Î±+ dendritic cells accumulate in tissues in elderly mice. Immunity and Ageing, 2014, 11, 11.	4.2	8
20	Targeting macrophages rescues ageâ€related immune deficiencies in C57<scp>BL</scp>/6J geriatric mice. Aging Cell, 2013, 12, 345-357.	6.7	133
21	Rapid Copper Acquisition by Developing Murine Mesothelioma: Decreasing Bioavailable Copper Slows Tumor Growth, Normalizes Vessels and Promotes T Cell Infiltration. PLoS ONE, 2013, 8, e73684.	2.5	36
22	Turning the tumor microenvironment into a self vaccine site. OncoImmunology, 2012, 1, 989-991.	4.6	3
23	IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. International Immunology, 2012, 24, 357-368.	4.0	31
24	The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer. International Reviews of Immunology, 2012, 31, 246-266.	3.3	69
25	Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo. Cancer Immunology, Immunotherapy, 2012, 61, 2343-2356.	4.2	84
26	Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses. Cancer Immunology, Immunotherapy, 2012, 61, 549-560.	4.2	38
27	CD40â€activated B cells contribute to mesothelioma tumor regression. Immunology and Cell Biology, 2011, 89, 255-267.	2.3	53
28	Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution. Cancer Gene Therapy, 2010, 17, 429-440.	4.6	16
29	Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. European Respiratory Journal, 2009, 34, 162-175.	6.7	26
30	Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. International Immunology, 2008, 20, 1467-1479.	4.0	71
31	Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. Journal of Clinical Investigation, 2008, 118, 1691-1699.	8.2	55
32	Tumor growth or regression: powered by inflammation. Journal of Leukocyte Biology, 2006, 80, 685-690.	3.3	50
33	Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunology, Immunotherapy, 2006, 55, 933-947.	4.2	7
34	Intratumoral Poly-N-Acetyl Glucosamine-Based Polymer Matrix Provokes a Prolonged Local Inflammatory Response That, When Combined with IL-2, Induces Regression of Malignant Mesothelioma in a Murine Model. Journal of Immunotherapy, 2005, 28, 359-367.	2.4	10
35	Gene therapy of mesothelioma. Expert Opinion on Biological Therapy, 2005, 5, 1039-1049.	3.1	5
36	Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Therapy, 2003, 10, 591-602.	4.6	11

#	Article	IF	Citations
37	IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2. Journal of Immunology, 2003, 171, 5051-5063.	0.8	196
38	Basic science funding in Australia: lessons from the EU. Nature Immunology, 2002, 3, 885-885.	14.5	0
39	The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Therapy, 2001, 8, 580-588.	4.6	38
40	Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective â€œArmingâ€•of Tumor Antigen-Specific CTL. Journal of Immunology, 2001, 166, 5557-5566.	0.8	60
41	In Vivo Cross-Presentation of a Soluble Protein Antigen: Kinetics, Distribution, and Generation of Effector CTL Recognizing Dominant and Subdominant Epitopes. Journal of Immunology, 2000, 165, 6123-6132.	0.8	60
42	Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation. Immunology and Cell Biology, 1999, 77, 552-558.	2.3	21
43	Effect of Ozone Exposure on Alveolar Macrophage-Mediated Immunosuppressive Activity in Rats. Toxicological Sciences, 1998, 41, 217-223.	3.1	10
44	Dendritic Cells Are Recruited into the Airway Epithelium during the Inflammatory Response to a Broad Spectrum of Stimuli. Journal of Experimental Medicine, 1996, 184, 2429-2432.	8.5	309